34.80
0.57%
-0.20
After Hours:
34.81
0.01
+0.03%
Tg Therapeutics Inc stock is traded at $34.80, with a volume of 1.23M.
It is down -0.57% in the last 24 hours and up +35.36% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
See More
Previous Close:
$35.00
Open:
$35.19
24h Volume:
1.23M
Relative Volume:
0.34
Market Cap:
$5.42B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-124.29
EPS:
-0.28
Net Cash Flow:
$67.82M
1W Performance:
-0.77%
1M Performance:
+35.36%
6M Performance:
+112.71%
1Y Performance:
+178.62%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
34.80 | 5.42B | 264.79M | -14.36M | 67.82M | -0.11 |
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-29-24 | Initiated | TD Cowen | Buy |
Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
Jun-26-23 | Resumed | Jefferies | Buy |
May-20-22 | Initiated | BofA Securities | Underperform |
Feb-23-22 | Reiterated | B. Riley Securities | Buy |
Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
Apr-20-21 | Initiated | Goldman | Neutral |
Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
Sep-01-20 | Initiated | JP Morgan | Overweight |
Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
Jun-05-20 | Initiated | Evercore ISI | Outperform |
Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
Nov-27-19 | Resumed | B. Riley FBR | Buy |
Feb-06-19 | Resumed | Jefferies | Buy |
Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
Nov-14-17 | Resumed | H.C. Wainwright | Buy |
Apr-25-17 | Initiated | Jefferies | Buy |
Mar-06-17 | Reiterated | FBR & Co. | Outperform |
Oct-06-16 | Resumed | Brean Capital | Buy |
May-27-16 | Initiated | SunTrust | Buy |
Dec-01-15 | Initiated | FBR Capital | Outperform |
Sep-09-15 | Initiated | Raymond James | Strong Buy |
Aug-12-15 | Resumed | H.C. Wainwright | Buy |
Jun-19-15 | Reiterated | Brean Capital | Buy |
Dec-11-14 | Reiterated | ROTH Capital | Buy |
Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
TG Therapeutics to Participate in the Evercore HealthCONx Conference - The Manila Times
TG Therapeutics CEO to Present at Evercore HealthCONx Conference | TGTX Stock News - StockTitan
TG Therapeutics to Participate in the Evercore HealthCONx Conference - GlobeNewswire Inc.
Thrivent Financial for Lutherans Acquires New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Mutual of America Capital Management LLC Invests $469,000 in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Algert Global LLC Sells 42,966 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics price target raised to $43 from $30 at JPMorgan - Yahoo Finance
Penserra Capital Management LLC Raises Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
(TGTX) Investment Analysis - Stock Traders Daily
TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
TG Therapeutics (NASDAQ:TGTX) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $43.00 - MarketBeat
Eagle Asset Management Inc. Makes New $3.95 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
52,390 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Segall Bryant & Hamill LLC - MarketBeat
NYC biotech venture tops Deloitte's Technology Fast 500 - The Business Journals
TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook - GuruFocus.com
A Closer Look at TG Therapeutics's Options Market Dynamics - Benzinga
Deloitte Unveils 2024 North America Technology Fast 500™ Rankings - The Malaysian Reserve
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - The Manila Times
TG Therapeutics Claims #1 Spot on Deloitte Fast 500 List, Driven by MS Drug Success | TGTX Stock News - StockTitan
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte - The Bakersfield Californian
TG Therapeutics Ranked Number One Fastest-Growing Company - GlobeNewswire
Oppenheimer & Co. Inc. Invests $759,000 in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
When (TGTX) Moves Investors should Listen - Stock Traders Daily
Entropy Technologies LP Purchases Shares of 31,200 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Principal Financial Group Inc. Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Amalgamated Bank - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Los Angeles Capital Management LLC - MarketBeat
Insider Sale: Director Laurence Charney Sells 25,000 Shares of T - GuruFocus.com
Insider Sale: Director Sagar Lonial Sells 5,000 Shares of TG The - GuruFocus.com
New York State Teachers Retirement System Invests $1 Million in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Don't Ignore The Insider Selling In TG Therapeutics - Simply Wall St
TG Therapeutics stock hits 52-week high at $28.43 - Investing.com India
TG Therapeutics stock hits 52-week high at $28.43 By Investing.com - Investing.com Canada
FY2024 EPS Estimates for TG Therapeutics Raised by Analyst - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Sets New 1-Year HighWhat's Next? - MarketBeat
FY2027 EPS Forecast for TG Therapeutics Decreased by Analyst - MarketBeat
Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking - Simply Wall St
TG Therapeutics, Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance
FY2024 EPS Estimates for TG Therapeutics Lowered by Analyst - MarketBeat
HC Wainwright Boosts Earnings Estimates for TG Therapeutics - MarketBeat
TG Therapeutics Inc (TGTX) Q3 2024 Earnings: Revenue Hits $83.3M, EPS at $0.02, Surpassing Estimates - GuruFocus.com
HC Wainwright Increases TG Therapeutics (NASDAQ:TGTX) Price Target to $55.00 - MarketBeat
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $22.00 at The Goldman Sachs Group - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Announces Earnings Results - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2024 Earnings Call Transcript - Insider Monkey
TG Therapeutics price target raised to $45 from $43 at Ladenburg - TipRanks
TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):